Egalet names Patrick Shea as chief commercial officer

19 September 2016

US specialty pharma group Egalet Corp (Nasdaq: EGLT) has today announced the appointment of Patrick Shea as chief commercial officer (CCO). Mr Shea will be responsible for leading Egalet's commercial activities and will report to Bob Radie, Egalet's chief executive officer.

In his role Mr Shea will be responsible for developing and implementing the commercialization strategy for Oxaydo (oxycodone HCI, USP) tablets for oral use only - CII, Sprix (ketorolac tromethamine) Nasal Spray, Arymo ER (morphine sulfate) extended-release tablets which is under review at the US Food and Drug Administration and additional Guardian Technology pipeline products as they are developed.

"With his extensive pharmaceutical and biotechnology sales and marketing experience, including his intimate knowledge of payor dynamics and product launch leadership, Pat will be an extremely valuable asset to Egalet as we prepare to launch Arymo ER, pending FDA approval, in the first quarter of 2017," said Mr Radie.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK